Development of
Alzheimer's disease
amyloid beta
carbon-11
radiolabeling
radiosynthesis
Journal
Journal of labelled compounds & radiopharmaceuticals
ISSN: 1099-1344
Titre abrégé: J Labelled Comp Radiopharm
Pays: England
ID NLM: 7610510
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
02
07
2023
received:
27
04
2023
accepted:
11
08
2023
medline:
4
10
2023
pubmed:
1
9
2023
entrez:
1
9
2023
Statut:
ppublish
Résumé
CRANAD-102, a selective near-infrared fluorescent tracer targeting soluble amyloid-β (Aβ) species, has recently attracted attention due to its potential to be used as a diagnostic tool for early stages of Alzheimer's disease (AD). Development of a positron emission tomography (PET) tracer based on CRANAD-102 could as such allow to noninvasively study soluble and protofibrillar species of Aβ in humans. These soluble and protofibrillar species are thought to be responsible to cause AD. Within this work, we successfully
Substances chimiques
Amyloid beta-Peptides
0
Fluorescent Dyes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
393-399Informations de copyright
© 2023 John Wiley & Sons, Ltd.
Références
Kristensen JL, Herth MM. Textbook of Drug Design and Discovery: In Vivo Imaging in Drug Discovery. Fifth edited. CRC Press; 2017.
Suppiah S, Didier MA, Vinjamuri S. The who, when, why, and how of PET amyloid imaging in management of Alzheimer's disease-review of literature and interesting images. Diagnostics. 2019;(2):65. doi:10.3390/diagnostics9020065
Cohen SIA, Arosio P, Presto J, et al. A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers. Nat Struct Mol Biol. 2015;22(3):207-213. doi:10.1038/nsmb.2971
Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416(6880):535-539. doi:10.1038/416535a
Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci. 2012;29(3):349-357. doi:10.1038/nn.3028
Lee SJC, Nam E, Lee HJ, Savelieff MG, Lim MH. Towards an understanding of amyloid-β oligomers: characterization, toxicity mechanisms, and inhibitors. Chem Soc Rev. 2017;46(2):310-323. doi:10.1039/C6CS00731G
Reiss AB, Arain HA, Stecker MM, Siegart NM, Kasselman LJ. Amyloid Toxicity in Alzheimer's Disease. Reviews in the Neurosciences. Walter de Gruyter GmbH; 2018:613-627.
Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ Protofibril antibody. Alzheimer's Res Ther. 2021;13:1-14.
Sehlin D, Fang XT, Cato L, Antoni G, Lannfelt L, Syvänen S. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease. Nat Commun. 2016;7:1-11.
Meier SR, Syvänen S, Hultqvist G, et al. Antibody-based in vivo PET imaging detects amyloid-ß reduction in Alzheimer transgenic mice after BACE-1 inhibition. J Nucl Med. 2018;59:1901-1906.
Lopes van den Broek S, Shalgunov V, García Vázquez R, et al. Pretargeted imaging beyond the blood-brain barrier-utopia or feasible? Pharmaceuticals. 2022;15(10):1191. doi:10.3390/ph15101191
Heller GT, Aprile FA, Michaels TCT, et al. Small-molecule sequestration of amyloid-β as a drug discovery strategy for Alzheimer's disease. Sci Adv. 2020;6:45. doi:10.1126/sciadv.abb5924
Chongzhao R, Xiaoyin X, Raymond SB, et al. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-β deposits. J am Chem Soc. 2009;131:15257-15261.
Zhang X, Tian Y, Li Z, et al. Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid Beta species in Alzheimer's disease. J am Chem Soc. 2013;135(44):16397-16409. doi:10.1021/ja405239v
Zhang X, Tian Y, Zhang C, et al. Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease. Proc Natl Acad Sci U S a. 2015;112(31):9734-9739. doi:10.1073/pnas.1505420112
Liu Y, Zhuang D, Wang J, et al. Recent advances in small molecular near-infrared fluorescence probes for a targeted diagnosis of the Alzheimer disease. Analyst. 2022;147:4701-4723. doi:10.1039/D2AN01327D
Li Y, Yang J, Liu H, et al. Tuning the stereo-hindrance of a curcumin scaffold for the selective imaging of the soluble forms of amyloid beta species. Chem Sci. 2017;8(11):7710-7717. doi:10.1039/C7SC02050C
Larsen P, Ulin J, Dahlstrøm K, Jensen M. Synthesis of [11C]Iodomethane by iodination of [11C]methane. Appl Radiat Isot. 1997;48(2):153-157. doi:10.1016/S0969-8043(96)00177-7
Herth MM, Ametamey S, Antuganov D, et al. On the consensus nomenclature rules for radiopharmaceutical chemistry-reconsideration of radiochemical conversion. Nucl Med Biol. 2021;93:19-21. doi:10.1016/j.nucmedbio.2020.11.003
Andersen VL, Herth MM, Lehel S, Knudsen GM, Kristensen JL. Palladium-mediated conversion of para-aminoarylboronic esters into para-aminoaryl-11C-methanes. Tetrahedron Lett. 2013;54(3):213-216. doi:10.1016/j.tetlet.2012.11.001
Herth MM, Andersen VL, Hansen HD, et al. Evaluation of 3-ethyl-3-(phenylpiperazinylbutyl)oxindoles as PET ligands for the serotonin 5-HT7 receptor: synthesis, pharmacology, radiolabeling, and in vivo brain imaging in pigs. J Med Chem. 2015;58(8):3631-3636. doi:10.1021/acs.jmedchem.5b00095
Andersen VL, Hansen HD, Herth MM, Knudsen GM, Kristensen JL. 11C-labeling and preliminary evaluation of Vortioxetine as a PET Radioligand. Bioorg Med Chem Lett. 2014;24(11):2408-2411. doi:10.1016/j.bmcl.2014.04.044
Hansen HD, Herth MM, Ettrup A, et al. Radiosynthesis and in vivo evaluation of novel radioligands for pet imaging of cerebral 5-HT7 receptors. J Nucl Med. 2014;55(4):640-646. doi:10.2967/jnumed.113.128983